From: Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression
Ā | Subgroup I | Subgroup II | Subgroup III | Subgroup IV |
---|---|---|---|---|
Ā | CD8high PD-L1ā | CD8high PD-L1+ | CD8low PD-L1ā | CD8low PD-L1+ |
Clinical parameters n (%) | (nā=ā12) | (nā=ā21) | (nā=ā18) | (nā=ā15) |
Age median (range) | 65 (50ā79) | 64 (29ā75) | 66 (48ā79) | 70 (45ā81) |
Sex (Female) | 7 (58%) | 12 (57%) | 10 (56%) | 9 (60%) |
TNM stage (IIIā+āIV) | 7 (58%) | 11 (52%) | 14 (78%) | 11 (73%) |
Risk factors | ||||
āGallstone | 3 (25%) | 13 (62%) | 11 (61%) | 9 (60%) |
āDiabetes | 4 (33%) | 6 (29%) | 7 (39%) | 3 (20%) |
āHypertension | 4 (33%) | 8 (38%) | 8 (44%) | 5 (33%) |
āCholecystitis | 7 (58%) | 12 (57%) | 14 (78%) | 10 (67%) |
Jaundice | 0 (0%) | 6 (29%) | 4 (22%) | 4 (27%) |
Completed resection | 8 (67%) | 16 (76%) | 11 (61%) | 11 (73%) |
CEA (>ā 5Ā Ī¼g/L) | 2 (17%) | 5 (24%) | 4 (22%) | 9 (60%) |
CA19ā9 (>ā 34Ā U/mL) | 4 (33%) | 13 (62%) | 11 (61%) | 7 (58%) |
Liver dysfunction | ||||
āALT (>ā 40Ā U/L) | Ā | Ā | Ā | Ā |
āAST (>ā 35Ā U/L) | 1 (8%) | 5 (24%) | 5 (28%) | 4 (27%) |
āTBil (>ā 22.2Ā Ī¼mol/L) | 3 (25%) | 5 (24%) | 6 (33%) | 5 (33%) |
āDBil (>ā 6.8Ā Ī¼mol/L) | 3 (25%) | 7 (33%) | 5 (28%) | 5 (33%) |
āGGT (>ā 45Ā U/L) | 1 (8%) | 7 (33%) | 5 (28%) | 5 (33%) |
āALP (>ā 135Ā U/L) | 3 (25%) | 7 (33%) | 5 (28%) | 5 (33%) |
Ā | 2 (17%) | 9 (43%) | 5 (28%) | 4 (27%) |
Pathological features | ||||
Differentiation (Poor) | 5 (42%) | 12 (57%) | 9 (50%) | 12 (80%) |
Tumor size, cm (median, range) | 2.4 (0.6ā7.5) | 3.5 (0.5ā7.0) | 3.0 (0.6ā6.0) | 2.0 (0.8ā7.0) |
Immunohistochemistry | ||||
āCD133+ in TCs, n (%) | 5 (42%) | 9 (43%) | 6 (33%) | 7 (58%) |
āPD-1+ in TILs, n (%) | 7 (58%) | 9 (43%) | 6 (33%) | 11 (73%) |
āPD-L2+ in TCs, n (%) | 5 (42%) | 17 (81%) | 9 (50%) | 13 (87%) |
āCD8+ TILs density | 60.5 | 79 | 28 | 27 |
ā(median, range) | (47ā167) | (49ā275) | (4ā42) | (8ā46) |
Adjuvant treatment | ||||
āChemotherapy, n (%) | 7 (58%) | 12 (57%) | 13 (72%) | 8 (53%) |
āRadiotherapy, n (%) | 2 (17%) | 5 (24%) | 4 (22%) | 4 (27%) |
āOthers, n (%) | 3 (25%) | 8 (33%) | 6 (33%) | 4 (27%) |
āNo, n (%) | 2 (17%) | 4 (19%) | 2 (11%) | 2 (13%) |
Palliative treatment at stage IV | ||||
āWith therapy, n (%) | 8 (67%) | 16 (76%) | 15 (83%) | 12 (80%) |
āWithout therapy, n (%) | 4 (33%) | 5 (24%) | 3 (17%) | 3 (20%) |